Search details
1.
Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.
Am J Hum Genet
; 109(1): 136-156, 2022 01 06.
Article
in English
| MEDLINE | ID: mdl-34890546
2.
Matrix Metalloproteinase-7 in Urinary Extracellular Vesicles Identifies Rapid Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
J Am Soc Nephrol
; 35(3): 321-334, 2024 Mar 01.
Article
in English
| MEDLINE | ID: mdl-38073039
3.
Effects of salt and protein intake on polyuria in V2RA-treated ADPKD patients.
Nephrol Dial Transplant
; 39(4): 707-716, 2024 Mar 27.
Article
in English
| MEDLINE | ID: mdl-37804179
4.
Kidney phosphate wasting predicts poor outcome in polycystic kidney disease.
Nephrol Dial Transplant
; 2023 Nov 20.
Article
in English
| MEDLINE | ID: mdl-37985930
5.
Multidisciplinary management of chronic refractory pain in autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant
; 38(3): 618-629, 2023 02 28.
Article
in English
| MEDLINE | ID: mdl-35512573
6.
The impact of pre-transplantation nephrectomy on quality of life in patients with autosomal dominant polycystic kidney disease.
World J Urol
; 41(4): 1193-1203, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36930253
7.
The Need for Routine Native Nephrectomy in the Workup for Kidney Transplantation in Autosomal Dominant Polycystic Kidney Disease Patients.
Urol Int
; 107(2): 148-156, 2023.
Article
in English
| MEDLINE | ID: mdl-35810740
8.
Emerging non-pharmacological interventions in ADPKD: an update on dietary advices for clinical practice.
Curr Opin Nephrol Hypertens
; 30(5): 482-492, 2021 09 01.
Article
in English
| MEDLINE | ID: mdl-34261861
9.
Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study.
Nephrol Dial Transplant
; 36(10): 1828-1836, 2021 09 27.
Article
in English
| MEDLINE | ID: mdl-33150452
10.
Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease.
Kidney Int
; 98(4): 989-998, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32534051
11.
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
Gastroenterology
; 157(2): 481-491.e7, 2019 08.
Article
in English
| MEDLINE | ID: mdl-31022403
12.
Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant
; 35(8): 1306-1316, 2020 08 01.
Article
in English
| MEDLINE | ID: mdl-31077332
13.
Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
Am J Kidney Dis
; 73(3): 354-362, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30578153
14.
Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
Am J Nephrol
; 50(5): 375-385, 2019.
Article
in English
| MEDLINE | ID: mdl-31600749
15.
Case report: a thiazide diuretic to treat polyuria induced by tolvaptan.
BMC Nephrol
; 19(1): 157, 2018 07 03.
Article
in English
| MEDLINE | ID: mdl-29970015
16.
Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
BMC Nephrol
; 19(1): 368, 2018 12 19.
Article
in English
| MEDLINE | ID: mdl-30567514
17.
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
JAMA
; 320(19): 2010-2019, 2018 11 20.
Article
in English
| MEDLINE | ID: mdl-30422235
18.
Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients.
Clin Exp Nephrol
; 21(3): 375-382, 2017 Jun.
Article
in English
| MEDLINE | ID: mdl-27339446
19.
Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.
Am J Nephrol
; 44(3): 194-203, 2016.
Article
in English
| MEDLINE | ID: mdl-27578560
20.
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
Nephrol Dial Transplant
; 31(11): 1887-1894, 2016 11.
Article
in English
| MEDLINE | ID: mdl-26681730